http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 09:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Analyst+Comments/Biogen+%28BIIB%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+Advancing+with+BIIB080/26669914.html <p>Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and $206.00 price target on Biogen (NASDAQ: BIIB).</p><p>The analyst commented, "we do see outcomes where investment in BIIB080 can make business sense. We also see scenarios in which reasonable assumptions can't justify an investment. So the case for BIIB080 will likely be left up to the eye of the beholder. From our perspective, we still wonder why BIIB, of all companies, would want to reopen its past can of worms when the company seemingly has better investment opportunities in I&I and other indications.""</p><p>For an analyst ratings summary and ratings history on http://www.streetinsider.com/Analyst+Comments/Biogen+%28BIIB%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+Advancing+with+BIIB080/26669914.html Mon, 22 Jun 2026 07:33:34 -0400 BIIB http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Biogen+%28BIIB%29/26662711.html <p>Needham analyst Ami Fadia reiterated a Buy rating and $255.00 price target on Biogen (NASDAQ: BIIB).</p><p>The analyst commented: "Biogen disclosed the acquisition of RayThera (LINK) post-market close yesterday. This acquisition brings in multiple anti-inflammatory assets (3 based on the company website) that could potentially treat immune-mediated conditions across a range of indications with the lead candidate expected to enter Ph 1 development in early 3Q26. This acquisition continues the development of the immunology pipeline for biogen and brings in some early-stage assets to counter the current late-stage developmental pipeline. The PR noted the potential deal value of up to $1B http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Biogen+%28BIIB%29/26662711.html Thu, 18 Jun 2026 07:06:53 -0400 BIIB http://www.streetinsider.com/Mergers+and+Acquisitions/Biogen+to+acquire+RayThera+for+up+to+%241+billion/26661321.html <p>Biogen Inc. (Nasdaq: BIIB) has entered into a definitive agreement to acquire RayThera Inc., a private San Diego-based biotechnology company focused on small molecule therapies in immunology, for up to $1 billion.</p> <p>The deal consists of an upfront payment to RayThera shareholders plus contingent payments tied to the achievement of clinical and regulatory milestones, which represent the predominant portion of the total potential value. Specific upfront payment figures were not disclosed.</p> <p>RayThera's portfolio includes multiple anti-inflammatory assets targeting immune-mediated conditions across a range of indications. The company's lead candidate is expected to enter Phase 1 clinical development in early Q3 2026.</p> <p>The transaction http://www.streetinsider.com/Mergers+and+Acquisitions/Biogen+to+acquire+RayThera+for+up+to+%241+billion/26661321.html Wed, 17 Jun 2026 18:59:41 -0400 A.50216984 BIIB O.00070139 O.59171780